Tempest Therapeutics, Inc. — Earnings Release 2012

Nov 13, 2012

8-K 1 a12-26860_18k.htm 8-K

*UNITED STATES*

*SECURITIES AND EXCHANGE COMMISSION*

*WASHINGTON, D.C. 20549*

*FORM 8-K*

*CURRENT REPORT Pursuant to Section 13 or 15(d) of the*

*Securities Exchange Act of 1934*

Date of report (Date of earliest event reported): *November 13* , 2012

*OvaScience, Inc.*

(Exact Name of Registrant as Specified in Charter)

Delaware	000-54647	45-1472564
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)

215 First Street, Suite 240, Cambridge, MA	02142
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code: (617) 500-2802

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SEQ.=1,FOLIO='',FILE='C:\JMS\mvangb\12-26860-1\task5666700\26860-1-ba.htm',USER='mvangb',CD='Nov 13 12:36 2012'

*Item 2.02. Results of Operations and Financial Condition*

On November 13, 2012, OvaScience, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2012. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

*Item 9.01. Financial Statements and Exhibits*

(d) Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

99.1 Press Release dated November 13, 2012.

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\mvangb\12-26860-1\task5666700\26860-1-ba.htm',USER='mvangb',CD='Nov 13 12:36 2012'

*SIGNATURE*

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Christopher Bleck
Christopher Bleck
Chief Operating Officer

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\mvangb\12-26860-1\task5666700\26860-1-ba.htm',USER='mvangb',CD='Nov 13 12:36 2012'

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release entitled “ OvaScience Announces Third Quarter Fiscal 2012 Financial Results” issued by the Company on November 13, 2012.

4

SEQ.=1,FOLIO='4',FILE='C:\JMS\mvangb\12-26860-1\task5666700\26860-1-ba.htm',USER='mvangb',CD='Nov 13 12:36 2012'